论文信息 - Genetics in the era of targeted CLL therapy. - 字舞流文

Genetics in the era of targeted CLL therapy.

T. Stankovic | M. Kwok

[1] L. Bullinger,et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. , 2020, Blood.

[2] T. Kipps,et al. Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial , 2019, Blood.

[3] T. Kipps,et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study , 2019, Leukemia.

[4] T. Kipps,et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. , 2019, The New England journal of medicine.

[5] J. Byrd,et al. Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. , 2019, Blood.

[6] M. Peifer,et al. Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia , 2018, Nature Communications.

[7] M. Raffeld,et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. , 2017, Blood.

[8] Jeffrey A Jones,et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.

[9] Shuqiang Li,et al. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition , 2016, Nature Communications.